Two strong congressional committees investigating the controversial federal approval of Biogen’s Alzheimer’s drug Aduhelm requested extensive information and documentation from the Food and Drug Administration in a letter released Thursday, making it clear that committee leaders were annoyed by the unusual actions the agency took. during the evaluation and approval of the drug. “We are […]